Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM-201 in Relapsed/Refractory T-ALL or T-LLy
NCT06934382Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Gene Editing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BEAM-201 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) (2 arms). Primary endpoints: Maximum Tolerated Dose at 5 years and Adverse Events at 5 years. Started Apr 2025; status: recruiting.
02
Drugs
BEAM-201
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06934382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934382.